Clinical trial / 2012
Amla supplementation for 42 days significantly improved lipid profiles and reduced blood pressure in patients with type II hyperlipidemia.
Sixty type II hyperlipidemic patients were assigned to receive either 500 mg of Amla daily (n=40) or 20 mg of simvastatin daily (n=20) for 42 days. Treatment with Amla led to significant reductions in total cholesterol (P<0.0001), LDL (P<0.0001), triglycerides and VLDL (P<0.0002), along with a significant increase in HDL (P<0.0002). Simvastatin also significantly reduced TC (P<0.0001), LDL (P<0.0009), TG and VLDL (P<0.017), and increased HDL (P<0.0001). Both treatments significantly reduced blood pressure, with the beneficial effect reported as more marked in patients receiving Amla.
- Study type
- Comparative clinical trial
- Who was studied
- 60 patients of both sexes with type II hyperlipidemia (TC > 240 mg%, LDL > 130 mg%)
- What was measured
- Total cholesterol, LDL, HDL, VLDL, triglycerides, and blood pressure
THE PAPER
A comparative clinical study of hypolipidemic efficacy of Amla (Emblica officinalis) with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitor simvastatin.
Gopa B, Bhatt J, Hemavathi KG. Indian J Pharmacol, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.